Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Apr 16, 2019 7:51am
157 Views
Post# 29631802

What its worth/ What it takes

What its worth/ What it takesActually the market, on the canadian side, (cannabis apart) is having a difficult year. A lot more questions about a slump, the general conditions around the world seems to suggest that its coming soon, others are saying yes, "but not this year...".

For TH/THERF, that means a lot. People who bought the shares at 2$ - 3$......a couple of years ago are having the reflection: "So the profit his there on my side; the company accumulates good news, but the market gives the opposite response, and some other sectors perform better". What would you do ? And in Canada, yesterday, a company like PLI was literaly killed in refinancing, after a desaster in the last two years......

What is TH/THERF worth ? 7,50$ C. ? 10$ C ?

What will it take to attract buyers ? And to bring the value back to 1B$C ?

1. A continuous trend in sales of trogarzo (30% and more quarter after quarter);
2. A good bump in sales for EGRIFTA since the news about NASH;
3. Approval in EUROPE in may for TROGARZO;
4. Good detailed explanation of the full study from Grinspoon (NASH-EGRIFTA);
5. In June, (AND NOT AFTER !!!!), or before, a clear pathway from the company about WHAT EXACTLY THEY WILL SUBMIT TO FDA and regulation in EUROPE about EGRIFTA;
6. JULY: A REAL and GOOD profit in july (second quarter) that beats expectations of the market.

If all this occurs, than TH\THERF will look behind at the 52 year low that we are actually embracing.......

FTV.


Bullboard Posts